Netherlands· NL-082081fcd924
Ryzneuta 20 mg oplossing voor injectie
A efbemalenograstim alfa product containing efbemalenograstim alfa, registered in Netherlands by Fisiopharma S.r.L.. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Efbemalenograstim alfa is registered in 9 of 19 countries.
Countries holding a registration under ATC L03AA18 (efbemalenograstim alfa), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Efbemalenograstim alfa · ATC L03AA18
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- EFBEMALENOGRASTIM ALFA
- Manufacturer
- Fisiopharma S.r.L.
- Country
- Netherlands (NL)
- ATC code
- L03AA18
- ATC class
- Efbemalenograstim alfa
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1793
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Efbemalenograstim alfa in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandRyzneuta 20 mg solution for injectionFisiopharma SrL
- BelgiumRyzneuta 20 mgFisiopharma
- CzechiaRYZNEUTAFISIOPHARMA S.R.L., NUCLEO INDUSTRIALE, PALOMONTE
- FinlandRyzneutaFisiopharma S.r.l.
- IcelandRyzneutaEvive Biotechnology Ireland Limited
- PolandRyzneutaFisiopharma S.r.l.
- SwedenRyzneuta 20 mg Injektionsvätska, lösning i förfylld sprutaFisiopharma S.r.l.
- United StatesRYZNEUTAAcrotech Biopharma Inc
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ryzneuta
- Liechtenstein · Ryzneuta
- Norway · Ryzneuta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f3309198-2471-4c2a-b460-0464931388b7 GET /v1/drugs/f3309198-2471-4c2a-b460-0464931388b7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ryzneuta-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Efbemalenograstim Alfa",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128936",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"EDETAAT TETRANATRIUM",
"NATRIUMACETAAT 3-WATER (E 262)",
"POLYSORBAAT 20 (E 432)",
"SORBITOL (E 420)"
],
"substances": [
"EFBEMALENOGRASTIM ALFA"
],
"leaflet_url": null,
"authorised_at": "2024/03/21",
"procedure_number": "EMEA/H/C/005828",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1793",
"additional_monitoring": "Y"
}See everything about efbemalenograstim alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.